Johnson & Johnson (JNJ) Falls Despite Earnings Beat, Strong Olysio Sales

NEW YORK (TheStreet) -- Johnson & Johnson  (JNJ) fell Tuesday despite its second-quarter earnings report that beat analysts' expectations.

The healthcare company reported a 9.1% revenue increase to $19.5 billion, while analysts polled by Thomson Reuters expected $19 billion. The company's hepatitis C treatment Olysio climbed to $831 million worldwide for the quarter, up from $354 million in the first quarter and greater than most estimates.

Johnson & Johnson reported earnings per share of $1.51 and adjusted EPS of $1.66. Analysts polled by Thomson Reuters expected $1.55 a share.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The company also increased its full-year earnings guidance, excluding items, to a range of $5.85 to $5.92, up from its previous forecast of $5.80 to $5.90 a share.

The stock was down 1.31% to $104 at 10:34 a.m.

JNJ Price Chart

JNJ Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%